47
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Longitudinal Study of Motor, Oculomotor and Cognitive Function in Progressive Supranuclear Palsy

      research-article
      1 , 2 , * , 3 , 2 , 4 , 5
      PLoS ONE
      Public Library of Science

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          We studied the annual change in measures of motor, oculomotor and cognitive function in progressive supranuclear palsy. This had twin objectives, to assess the potential for clinical parameters to monitor disease progression in clinical trials and to illuminate the progression of pathophysiology.

          Methods

          Twenty three patients with progressive supranuclear palsy (Richardson’s syndrome) were compared to 22 matched controls at baseline and 16 of these patients compared at baseline and one year using: the progressive supranuclear palsy rating scale; the unified Parkinson’s disease rating scale; the revised Addenbrooke’s cognitive examination; the frontal assessment battery; the cubes section of the visual object and space perception battery; the Hayling and Brixton executive tests; and saccadic latencies.

          Results

          Patients were significantly impaired in all domains at baseline. However, cognitive performance was maintained over a year on the majority of tests. The unified Parkinson’s disease rating scale, saccadic latency and progressive supranuclear palsy rating scale deteriorated over a year, with the latter showing the largest change. Power estimates indicate that using the progressive supranuclear palsy rating scale as an outcome measure in a clinical trial would require 45 patients per arm, to identify a 50% reduction in rate of decline with 80% power.

          Conclusions

          Motor, oculomotor and cognitive domains deteriorate at different rates in progressive supranuclear palsy. This may be due to differential degeneration of their respective cortical-subcortical circuits, and has major implications for the selection of outcome measures in clinical trials due to wide variation in sensitivity to annual rates of decline.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: not found
          • Article: not found

          Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders.

            As there are no biological markers for the antemortem diagnosis of degenerative parkinsonian disorders, diagnosis currently relies upon the presence and progression of clinical features and confirmation depends on neuropathology. Clinicopathologic studies have shown significant false-positive and false-negative rates for diagnosing these disorders, and misdiagnosis is especially common during the early stages of these diseases. It is important to establish a set of widely accepted diagnostic criteria for these disorders that may be applied and reproduced in a blinded fashion. This review summarizes the findings of the SIC Task Force for the study of diagnostic criteria for parkinsonian disorders in the areas of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. In each of these areas, diagnosis continues to rest on clinical findings and the judicious use of ancillary studies. Copyright 2003 Movement Disorder Society
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A clinical rating scale for progressive supranuclear palsy.

              We devised a Progressive Supranuclear Palsy (PSP) Rating Scale comprising 28 items in six categories: daily activities (by history), behaviour, bulbar, ocular motor, limb motor and gait/midline. Scores range from 0 to 100, each item graded 0-2 (six items) or 0-4 (22 items). Inter-rater reliability is good, with intra-class correlation coefficient for the overall scale of 0.86 (95% CI 0.65-0.98). A single examiner applied the PSPRS at every visit for 162 patients. Mean rate of progression was 11.3 (+/-11.0) points per year. Neither onset age nor gender correlated well with rate of progression. Median actuarially corrected survival was 7.3 years. The PSPRS score was a good independent predictor of subsequent survival (P < 0.0001). For example, for patients with scores from 40 to 49, 3-year survival was 41.9% (95% CI 31.0-56.6) but 4-year survival was only 17.9% (95% CI 10.2-31.5). For those patients, likelihood or retaining some gait function was 51.7% (40.0-66.9) at 1 year but only 6.5% (1.8-23.5) at 3 years. We conclude that the PSPRS is a practical measure that is sensitive to disease progression and could be useful as a dependent variable in observational or interventional trials and as an indicator of prognosis in clinical practice.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, USA )
                1932-6203
                2013
                10 September 2013
                : 8
                : 9
                : e74486
                Affiliations
                [1 ]Wessex Neuroscience Centre, Southampton University Hospital NHS Trust, Southampton, Hampshire, United Kingdom
                [2 ]Department of Clinical Neurosciences, Cambridge University, Cambridge, Cambridgeshire, United Kingdom
                [3 ]Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom
                [4 ]MRC Cognition and Brain Sciences Unit, Cambridge, Cambridgeshire, United Kingdom
                [5 ]Behavioural and Clinical Neuroscience Institute, Cambridge, Cambridgeshire, United Kingdom
                Oslo University Hospital, Norway
                Author notes

                Competing Interests: I have read the journal's policy and Boyd Ghosh has the following conflicts: I have received grants to attend movement disorders meetings in Paris and Toronto from the Fearnside scholarship and the ABN travel grant respectively. I have received payment for lectures related to the differential diagnosis and management of Parkinson's plus disorders from the PSP Association and GlaxoSmithKline. I also serve on the PSP Association advisory panel. James Rowe declares the following: He has received an honorarium for lectures to the Copenhagen University Hospitals and fees for examination of PhD's. He also sits on the PSP association advisory board. Roger Carpenter was an unpaid director of Advanced Clinical Instrumentation that acted as a distributor for the saccadometer, but ceased that role in 2011. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

                Conceived and designed the experiments: BCPG JBR. Performed the experiments: BCPG JBR. Analyzed the data: BCPG RHSC JBR. Contributed reagents/materials/analysis tools: RHSC JBR. Wrote the manuscript: BCPG RHSC JBR.

                Article
                PONE-D-13-14186
                10.1371/journal.pone.0074486
                3769232
                24058574
                543eaf61-0255-4473-a03c-920f1cc72080
                Copyright @ 2013

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 8 April 2013
                : 2 August 2013
                Funding
                This work was supported by the Medical Research Council [G0700503 to BG]; the Guarantors of Brain (BG); the Raymond and Beverley Sackler Trust (BG). JR is supported by the Wellcome Trust [088324] and the Cambridge NIHR Comprehensive Biomedical Research Centre including the Cambridge Brain Bank. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article